by Steve Schonberg | Oct 30, 2020 | Changemakers
Historians have long described the Spartans of ancient Greece as warriors—emotional and physical titans with an unbreakable spirit and a will to survive that’s nearly unparalleled. At Target ALS, we feel the same way about modern-day Spartans, the nickname for those...
by Steve Schonberg | Jul 7, 2020 | Changemakers
If you look at the ALS patient population it’s clear that the disease doesn’t discriminate. While most patients develop ALS between the ages of 40 and 70, cases can occur at any time in life. According to the ALS Association, men are 20% more likely to be diagnosed...
by Target ALS | Jun 8, 2020 | Changemakers
Earlier this month, Target ALS and The Association for Frontotemporal Degeneration (AFTD) announced six teams who will receive a portion of $5 million in funding for projects targeting the discovery of treatments and biomarkers* for ALS and FTD. Though FTD represents...
by Steve Schonberg | Dec 19, 2019 | Changemakers
In June, biotech giant Biogen launched a clinical trial for BIIB-100, one of the latest in their neurological disease pipeline designed to treat Amyotrophic Lateral Sclerosis (ALS)—commonly known as Lou Gehrig’s disease. Two things make this news particularly...
by Steve Schonberg | Dec 5, 2019 | Changemakers
In our world of incredible scientific advancements, it seems inconceivable that this year marks 150 years since ALS was first described, yet there remains no effective treatment for the disease. However, an innovative approach—created by nonprofit medical foundation...
by Steve Schonberg | Apr 26, 2019 | Changemakers
By Jonathan Saltzman, Globe Staff Read the full Boston Globe story...
